相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis
Takayuki Ando et al.
IN VIVO (2021)
Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
Xiaoxiang Zhou et al.
BMC MEDICINE (2020)
Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors
Denis Maillet et al.
EUROPEAN JOURNAL OF CANCER (2020)
Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
Hiroshi Matsuoka et al.
BMC CANCER (2020)
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial
Robert J. Motzer et al.
CANCER (2020)
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer
Bairavi Shankar et al.
JAMA ONCOLOGY (2020)
Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
Marion Allouchery et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
Hamzah Abu-Sbeih et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
Audrey Simonaggio et al.
JAMA ONCOLOGY (2019)
Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors
Jun Fukihara et al.
CLINICAL LUNG CANCER (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
Ken Masuda et al.
BMC CANCER (2019)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma
Hamzah Abu-Sbeih et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors
Alice de Malet et al.
EUROPEAN JOURNAL OF CANCER (2019)
Clinical characterization of colitis arising from anti-PD-1 based therapy
Daniel Y. Wang et al.
ONCOIMMUNOLOGY (2019)
Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO plus IPI: a systematic review and meta-analysis
Puyuan Xing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors
Heinz Laubli et al.
ONCOIMMUNOLOGY (2018)
Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis
Yinghong Wang et al.
INFLAMMATORY BOWEL DISEASES (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis
Parul Tandon et al.
JOURNAL OF IMMUNOTHERAPY (2018)
Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
Yinghong Wang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management
Marnix H. Geukes Foppen et al.
ESMO OPEN (2018)
Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis
Daniel Y. Wang et al.
ONCOIMMUNOLOGY (2017)
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
M. Collins et al.
ANNALS OF ONCOLOGY (2017)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria
M. J. Barnes et al.
MUCOSAL IMMUNOLOGY (2013)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN-γ-Induced B7-H1 Expression in Cholangiocytes
Ai-Yu Gong et al.
JOURNAL OF IMMUNOLOGY (2009)
The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands
Audrey L. Kinter et al.
JOURNAL OF IMMUNOLOGY (2008)
Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism
I Lee et al.
JOURNAL OF IMMUNOLOGY (2003)
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses
SC Liang et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
分享论文
